Hematologic response to therapy
| Type of response . | No. (%)* . |
|---|---|
| Overall hematologic response | 16 (67) |
| Lenalidomide alone | 7 |
| Lenalidomide + dexamethasone | 9 |
| Hematologic CR | 7 (29) |
| Lenalidomide alone | 2 |
| Lenalidomide + dexamethasone | 5 |
| Hematologic PR | 9 (38) |
| Lenalidomide alone | 5 |
| Lenalidomide + dexamethasone | 4 |
| Type of response . | No. (%)* . |
|---|---|
| Overall hematologic response | 16 (67) |
| Lenalidomide alone | 7 |
| Lenalidomide + dexamethasone | 9 |
| Hematologic CR | 7 (29) |
| Lenalidomide alone | 2 |
| Lenalidomide + dexamethasone | 5 |
| Hematologic PR | 9 (38) |
| Lenalidomide alone | 5 |
| Lenalidomide + dexamethasone | 4 |
Percentages are out of 24 patients who received at least 3 cycles of lenalidomide treatment.
CR indicates complete response; PR, partial response.